Stockman Wealth Management Inc. Sells 4,295 Shares of Bristol-Myers Squibb Company (BMY)
Stockman Wealth Management Inc. decreased its position in Bristol-Myers Squibb Company (NYSE:BMY) by 15.5% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,335 shares of the biopharmaceutical company’s stock after selling 4,295 shares during the period. Stockman Wealth Management Inc.’s holdings in Bristol-Myers Squibb were worth $1,269,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. American National Bank raised its holdings in Bristol-Myers Squibb by 36.0% in the 1st quarter. American National Bank now owns 1,919 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 508 shares in the last quarter. Welch Investments LLC raised its holdings in Bristol-Myers Squibb by 3.9% in the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 79 shares in the last quarter. Crestwood Advisors Group LLC acquired a new position in Bristol-Myers Squibb in the 1st quarter valued at approximately $116,000. Blue Chip Partners Inc. raised its holdings in Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after acquiring an additional 17 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its holdings in Bristol-Myers Squibb by 2.8% in the 1st quarter. State of Alaska Department of Revenue now owns 2,229 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 60 shares in the last quarter. 68.80% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have commented on the company. BidaskClub raised Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $64.20 price target for the company. in a report on Tuesday, August 22nd. Deutsche Bank AG set a $55.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Monday, July 17th. Credit Suisse Group set a $58.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a report on Wednesday, August 16th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average price target of $62.54.
In other news, Director Theodore R. Samuels II acquired 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The stock was acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the transaction, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 0.23% of the stock is owned by insiders.
Bristol-Myers Squibb Company (BMY) traded down 0.41% during midday trading on Friday, reaching $62.58. The company had a trading volume of 3,101,789 shares. The stock’s 50 day moving average is $57.32 and its 200 day moving average is $55.65. The company has a market capitalization of $102.63 billion, a PE ratio of 22.86 and a beta of 1.18. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $63.47.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, beating the consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. During the same period in the previous year, the business earned $0.69 earnings per share. The company’s revenue was up 5.6% on a year-over-year basis. Equities research analysts forecast that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.